<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="correction" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2025.1658958</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Correction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Correction: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer&#x2014;an open-label phase 2 randomized controlled trial</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ramani</surname>
<given-names>Vinod K.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2377884/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sadashivaiah</surname>
<given-names>Ajaikumar Basavalinga</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Naik</surname>
<given-names>Radheshyam</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Preventive Oncology, Healthcare Global</institution>, <addr-line>Bangalore</addr-line>, <country>India</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Radiation Oncology, Healthcare Global</institution>, <addr-line>Bangalore</addr-line>, <country>India</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Medical Oncology, Healthcare Global</institution>, <addr-line>Bangalore</addr-line>, <country>India</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Vinod K. Ramani, <email xlink:href="mailto:drvinod.r@hcgel.com">drvinod.r@hcgel.com</email>
</p>
</fn>
<fn fn-type="other" id="fn003">
<p>&#x2020;ORCID: Vinod K. Ramani, <uri xlink:href="https://orcid.org/0000-0002-6531-9579">orcid.org/0000-0002-6531-9579</uri>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>15</volume>
<elocation-id>1658958</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>07</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>07</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Ramani, Sadashivaiah and Naik.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Ramani, Sadashivaiah and Naik</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" journal-id="Front Oncol" journal-id-type="nlm-ta" xlink:href="10.3389/fonc.2025.1561692" ext-link-type="doi">A Correction on <article-title>Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer&#x2014;an open-label phase 2 randomized controlled trial</article-title> By Ramani VK, Basavalinga Sadashivaiah A and Naik R (2025) <italic>Front. Oncol.</italic>&#xa0;15:1561692. doi:&#xa0;<object-id>10.3389/fonc.2025.1561692</object-id>
</related-article>
<kwd-group>
<kwd>metformin</kwd>
<kwd>survival analysis</kwd>
<kwd>triple negative breast neoplasm</kwd>
<kwd>remission</kwd>
<kwd>neoadjuvant</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="1"/>
<word-count count="123"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Breast Cancer</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>In the published article, there was an error in the affiliation of the first author. Instead of &#x201c;Preventive Oncology, Sammprada Cancer Hospital, Bangalore, India&#x201d;, it should be &#x201c;Preventive Oncology, Healthcare Global, Bangalore, India&#x201d;.</p>
<p>In the published article, there was an error in the affiliation of the third author. Instead of &#x201c;Preventive Oncology, Sammprada Cancer Hospital, Bangalore, India&#x201d;, it should be &#x201c;Medical Oncology, Healthcare Global, Bangalore, India&#x201d;.</p>
<p>The corresponding author email was erroneously given as: vinodramani77@gmail.com. The correct email address is: drvinod.r@hcgel.com.</p>
<p>The original version of this article has been updated.</p>
</body>
<back>
<sec id="s1" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</back>
</article>